How Much Do Pharma Companies Spend on Doctors?

The $13.9B Total

The CMS Open Payments program requires pharmaceutical manufacturers, biologic companies, and medical device makers to publicly disclose every payment above $10 made to a physician or teaching hospital. In Program Year 2024, covering payments made between January 1 and December 31, 2024, companies reported a combined $13.9B across millions of individual transactions.

That figure is roughly the size of a mid-cap pharmaceutical company's annual revenue. It covers everything from a $12 lunch for a primary care physician to multi-million-dollar research grants at academic medical centers. Understanding where that money flows, by category, by company, and by geography, is the core purpose of PlainPharmaWatch.

The 1,925 companies that report payments range from global pharmaceutical giants like Pfizer and AbbVie to small device manufacturers and specialty biotech firms. Together they represent the near-totality of the US prescription drug and medical device industry. Browse all reporting companies on PlainPharmaWatch.

Spending by Payment Category

The $13.9B is not distributed evenly across payment types. CMS's own General Payments categories account for 24.6% of the total; the remainder is Research and other payments, which CMS reports through a separate track that this portal does not break out by category:

Payment Category	Share of Total
Research & other (reported separately by CMS, not category-broken-out here)	75.4%
Royalty or License	6.2%
Compensation for Services Other Than Consulting	5.1%
Consulting Fee	4.1%
Food and Beverage	3.0%
Acquisitions	1.9%
Travel and Lodging	1.5%

Research payments (clinical trial funding and formal research agreements) are widely documented as the largest category nationally, they are expensive to run and the payments are large, but this portal's category chart above covers General Payments only. Among General Payments, the promotional categories, consulting, speaking, meals, generate the most policy concern because of their established links to prescribing behavior: a $13 lunch is a rounding error in total spending but statistically significant in its effect on brand-name prescribing. Explore all payment types in detail.

Top Spending Companies

Total payment spending is highly concentrated. A small number of large pharmaceutical companies account for a disproportionate share of all reported dollars. The top 10 companies by total payments in most recent program years share several common characteristics:

Blockbuster drug portfolios - companies with multiple top-selling branded products have both more resources for marketing and more physicians to target.
Active clinical pipelines - large research payments inflate total figures for companies running extensive Phase II and Phase III trials.
Specialty therapeutic focus - oncology, immunology, diabetes, and cardiovascular companies consistently dominate because specialists in these fields have significant prescribing authority over high-cost drugs.
Speaker bureau programs - companies that rely heavily on physician-to-physician education (a common pharma promotional tactic) generate large speaking and consulting fee totals.

PlainPharmaWatch includes detailed profiles for every company in the Open Payments database. You can sort by total payments, transaction count, number of physicians reached, or by state. Browse company profiles to see full breakdowns including payment type distributions and year-over-year comparisons.

Year-Over-Year Trends

Open Payments data goes back to 2013, providing over a decade of trend information. Several notable patterns have emerged:

Growth in Research Spending

Clinical trial spending has grown steadily as pharmaceutical R&D costs have escalated. The FDA's increasing focus on real-world evidence and post-market studies has also expanded the universe of research payments that companies must report. This growth is largely structural, it reflects the rising cost of drug development rather than increasing industry influence over physicians.

Decline in Speaker Bureau Activity

Following the opioid crisis and increased scrutiny of pharmaceutical marketing practices, many large companies reduced or eliminated their speaker bureau programs in the late 2010s. Johnson & Johnson, Allergan, and several other major companies exited the business. Reported speaking fee totals declined noticeably after 2016. Some companies have since re-entered speaker bureau programs for newer products.

Concentration in Specialty Drugs

As pharmaceutical revenue increasingly flows from high-cost specialty drugs (cancer immunotherapy, GLP-1 diabetes drugs, biologics for immune conditions), payments have concentrated in the specialists who prescribe them, oncologists, rheumatologists, endocrinologists, and neurologists. Primary care physicians have seen relatively flat or declining payment levels as industry shifts focus toward specialist audiences.

COVID-19 Impact (2020–2021)

Reported payments dropped significantly in 2020 as in-person medical conferences and office visits were suspended during the pandemic. Food and beverage payments, which typically require in-person office visits, fell sharply. Conference-related payments also declined. Total payment volumes partially recovered in 2021 and more fully by 2022–2023 as in-person industry activities resumed.

Geographic Distribution

Payments are not evenly distributed across the United States. States with large populations, major academic medical centers, and high concentrations of specialty physicians receive disproportionately large payment totals. In the current dataset, California, Florida, Pennsylvania, and Massachusetts rank in the top tier by total dollars received, partly because they have large physician populations, and partly because they are home to many of the country's top academic medical centers, which attract substantial research funding.

Per-physician payment levels tell a somewhat different story. States with prestigious academic medical centers (Massachusetts, Minnesota, Maryland) often show higher per-physician averages because a relatively small number of high-paid academic physicians, running clinical trials, serving on advisory boards, and working as key opinion leaders, pull up the state average substantially. Explore state-level payment data on PlainPharmaWatch.

Putting the Numbers in Context

$13.9B sounds large, and it is. But it is useful to put it in context relative to other pharmaceutical industry numbers:

Metric	Annual Estimate
US prescription drug sales	~$550–600B
Total pharma industry R&D spend	~$100–120B
US pharma direct-to-consumer advertising	~$8–10B
Open Payments: Total reported (PY2024)	$13.9B
Open Payments: Research & other (reported separately by CMS)	$10.5B
Open Payments: General Payments only	$3.4B

The $3.4B in General Payments, the categories most tied to promotional and consulting activity, represents less than 1% of US prescription drug revenues, a small fraction, but one that research suggests generates returns that far exceed the cost. A single blockbuster drug generating $5–10 billion in annual revenue provides significant financial incentive to invest in physician relationship-building, even if the per-physician payment amounts appear modest.

What Transparency Reveals

The Open Payments data is one of the most detailed windows into pharmaceutical industry marketing that exists anywhere in the world. Few countries require this level of public disclosure. The data has enabled a generation of research linking payments to prescribing, contributed to legal investigations, and allowed journalists and patient advocates to hold companies and physicians accountable.

At the same time, the data has limits. It captures what was paid but not whether the relationship was appropriate. Large research payments often represent legitimate scientific partnerships. Many consulting relationships produce genuine value. The purpose of transparency is not to presume guilt but to provide the raw information that patients, researchers, and policymakers need to evaluate the physician-industry relationship clearly.

Use PlainPharmaWatch to explore the data behind the numbers. Search companies, browse states, or view top recipients to see how $13.9B breaks down in detail.

Frequently Asked Questions

How much do pharmaceutical companies spend on doctor payments each year?

In Program Year 2024, pharmaceutical and medical device companies reported $13.9B in payments to physicians and teaching hospitals, covering 1,925 companies and millions of individual transactions. This figure has grown substantially since the Open Payments program launched in 2013 with around $6.5 billion in reported transfers. The growth reflects both increased industry activity and expanded reporting requirements.

What is the largest category of pharma spending on doctors?

Research payments (clinical trial funding, research grants, and payments under formal research agreements) are widely documented as the largest category nationally, they flow through institutional agreements and are subject to separate oversight, distinct from promotional payments like speaking fees, consulting fees, and food. CMS reports Research payments through a separate track; PlainPharmaWatch's own category breakdown covers General Payments only, where Royalty or License and Compensation for Services are currently the largest reported categories.

Which companies spend the most on doctor payments?

Large integrated pharmaceutical companies, especially those with blockbuster drugs in competitive therapeutic areas like oncology, immunology, and diabetes, tend to top the spending rankings. In the current dataset, Novartis Pharmaceuticals Corporation, Pfizer Inc., ModernaTX, Inc., Eli Lilly and Company, and Abbvie Inc. rank among the highest reported total spenders. Research-heavy companies with active clinical pipelines also contribute large research payment totals that inflate their overall figures.

How do pharma payment levels compare to drug advertising spending?

Pharmaceutical companies spend significantly more on direct-to-consumer advertising than on individual physician payments. US pharma DTC advertising exceeded $8–9 billion annually in recent years. However, physician-directed marketing through speaking fees, consulting, and meals is considered by researchers to be more effective per dollar because it targets prescribers directly. The Open Payments data captures only the physician-directed portion of total pharma marketing spend, companies also fund medical education programs, conferences, and institutional partnerships that are not included.

Have pharma payments to doctors increased or decreased over time?

Promotional payment categories (speaking fees, consulting, food and beverage) have generally declined or plateaued over the past decade, partly in response to public scrutiny and internal company policies. Many large companies exited speaker bureau programs or reduced meal marketing following the opioid crisis. However, research-related payments have grown as companies invest in increasingly expensive late-stage clinical development. Total reported dollars have risen overall, driven primarily by research spending.

Are smaller pharma companies also required to report payments?

Yes. All applicable manufacturers, regardless of size, must report payments above the reporting threshold (originally $10 per-payment/$100 aggregate in 2013, CPI-adjusted annually to $13.07 per-payment/$130.66 aggregate for 2026). This includes small biotech companies, generic drug makers, and specialty device manufacturers. In PY2024, 1,925 distinct companies submitted reports. The vast majority of total dollars, however, are concentrated in a relatively small number of large companies with extensive promotional operations and clinical trial programs.

Sources

This content is for informational purposes only and does not constitute medical or legal advice. Reported payments do not imply wrongdoing or inappropriate conduct. Many physician-industry relationships are lawful and clinically beneficial. Dollar estimates for payment subcategories are approximate and based on historical CMS program year breakdowns. Always consult your healthcare provider for medical decisions.